Search Results
Search for other papers by Myungwoo Nam in
Google Scholar
PubMed
Search for other papers by Woojung Yang in
Google Scholar
PubMed
Search for other papers by Hye Sung Kim in
Google Scholar
PubMed
Search for other papers by Jewel Park in
Google Scholar
PubMed
Search for other papers by Gahee Park in
Google Scholar
PubMed
Search for other papers by Sukjun Kim in
Google Scholar
PubMed
Search for other papers by Sanghoon Song in
Google Scholar
PubMed
Search for other papers by Chan-Young Ock in
Google Scholar
PubMed
The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA
Search for other papers by Victor G Wang in
Google Scholar
PubMed
The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA
Search for other papers by Jeffrey H Chuang in
Google Scholar
PubMed
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA
Search for other papers by Young Kwang Chae in
Google Scholar
PubMed
tumor mutational burden (TMB) are considered. This variability has also been observed in clinical trials focusing on thyroid cancers ( Arora et al. 2019 , Garcia-Alvarez et al. 2022 ). Tumor-infiltrating lymphocytes (TILs) can be a potential
Search for other papers by Lucas Leite Cunha in
Google Scholar
PubMed
Search for other papers by Marjory Alana Marcello in
Google Scholar
PubMed
Search for other papers by Laura Sterian Ward in
Google Scholar
PubMed
, provides increased protection against subsequent reinfection with the same pathogen ( Murphy 2011 ). How do tumor-infiltrating lymphocytes (TILs) interfere with tumor progression? CD4+ T cells are central to the successful orchestration of the immune
Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Florian Bösch in
Google Scholar
PubMed
Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Katharina Brüwer in
Google Scholar
PubMed
Search for other papers by Annelore Altendorf-Hofmann in
Google Scholar
PubMed
Department of Internal Medicine 4, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Christoph J Auernhammer in
Google Scholar
PubMed
Department of Internal Medicine 4, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Christine Spitzweg in
Google Scholar
PubMed
Department of Medicine 3 and Comprehensive Cancer Center, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by C Benedikt Westphalen in
Google Scholar
PubMed
Department of Medicine 3 and Comprehensive Cancer Center, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Stefan Boeck in
Google Scholar
PubMed
Munich Cancer Registry (MCR) of the Munich Tumour Centre (TZM), Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Gabriele Schubert-Fritschle in
Google Scholar
PubMed
Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Jens Werner in
Google Scholar
PubMed
Department of Medicine 3 and Comprehensive Cancer Center, Ludwig-Maximilians-University Munich, Munich, Germany
Search for other papers by Volker Heinemann in
Google Scholar
PubMed
Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany
Search for other papers by Thomas Kirchner in
Google Scholar
PubMed
Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System, Ludwig-Maximilians-University of Munich, Munich, Germany
Search for other papers by Martin Angele in
Google Scholar
PubMed
Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany
Search for other papers by Thomas Knösel in
Google Scholar
PubMed
survival rate of 8.8 months (CI 95%: 3.9; 13.6 months) compared to 30.3 months (CI 95%: 12.2; 48.4 months) ( P > 0.05). Figure 2 Kaplan–Meier overall survival curves for patients divided into levels of tumor-infiltrating lymphocytes (TIL) ( P < 0
Endocrinology Department, ‘C.I. Parhon’ National Institute of Endocrinology, Bucharest, Romania
Search for other papers by Mirela Diana Ilie in
Google Scholar
PubMed
Pathology Department, Reference Center for Rare Pituitary Diseases HYPO, ‘Groupement Hospitalier Est’ Hospices Civils de Lyon, Bron, France
Search for other papers by Alexandre Vasiljevic in
Google Scholar
PubMed
Neurosurgery Department, Reference Center for Rare Pituitary Diseases HYPO, ‘Groupement Hospitalier Est’ Hospices Civils de Lyon, Bron, France
Search for other papers by Emmanuel Jouanneau in
Google Scholar
PubMed
Endocrinology Department, Reference Center for Rare Pituitary Diseases HYPO, ‘Groupement Hospitalier Est’ Hospices Civils de Lyon, Bron, France
Search for other papers by Gérald Raverot in
Google Scholar
PubMed
). Here, we present an overview of immunotherapy in pituitary carcinomas and aggressive pituitary tumors, starting with the rationale for using this therapeutic option and the implications of tumor-infiltrating lymphocytes (TILs) in anterior pituitary
Search for other papers by Soomin Ahn in
Google Scholar
PubMed
Search for other papers by Tae Hyuk Kim in
Google Scholar
PubMed
Search for other papers by Sun Wook Kim in
Google Scholar
PubMed
Search for other papers by Chang Seok Ki in
Google Scholar
PubMed
Search for other papers by Hye Won Jang in
Google Scholar
PubMed
Search for other papers by Jee Soo Kim in
Google Scholar
PubMed
Search for other papers by Jung Han Kim in
Google Scholar
PubMed
Search for other papers by Jun-Ho Choe in
Google Scholar
PubMed
Search for other papers by Jung Hee Shin in
Google Scholar
PubMed
Search for other papers by Soo Yeon Hahn in
Google Scholar
PubMed
Search for other papers by Young Lyun Oh in
Google Scholar
PubMed
Search for other papers by Jae Hoon Chung in
Google Scholar
PubMed
://dx.doi.org/10.1530/ERC-16-0421 . PD-L1 immunohistochemistry microscopy results were interpreted by two experienced pathologists (SA and YO). PD-L1 expression was evaluated in tumor cells and tumor-infiltrating lymphocytes. For tumor cells, positive PD
Search for other papers by Frank Weber in
Google Scholar
PubMed
pro-oncogenic and immunosuppressive to the ability to induce an effective host anti-tumor response ( Guarino et al . 2010 , Gogali et al . 2012 ). Tumor infiltrating lymphocytes and cancer progression The field of immunology expands at rapid pace
Search for other papers by Lucas Leite Cunha in
Google Scholar
PubMed
Search for other papers by Marjory Alana Marcello in
Google Scholar
PubMed
Search for other papers by Vinicius Rocha-Santos in
Google Scholar
PubMed
Search for other papers by Laura Sterian Ward in
Google Scholar
PubMed
, hematological malignancies and solid tumors are frequently enriched with tumor-infiltrating lymphocytes in which PD-1 is markedly upregulated, whereas the ligands PD-L1 and PD-L2 are expressed by various types of tumor cells, reinforcing the hypothesis that the
Department of Cellular Pathology, Queen Elizabeth Hospital Birmingham and University of Birmingham, Birmingham, UK
Search for other papers by Tom Lees in
Google Scholar
PubMed
Search for other papers by Angharad Cullinane in
Google Scholar
PubMed
Search for other papers by Alexandra Condon in
Google Scholar
PubMed
Search for other papers by Abeer M Shabaan in
Google Scholar
PubMed
Search for other papers by Matthew P Humphries in
Google Scholar
PubMed
Search for other papers by Valerie Speirs in
Google Scholar
PubMed
de Vijver K Estrada MV Gonzalez-Ericsson PI , et al . 2017 Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers
Department of Surgery, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA
Search for other papers by Ziqiang Yuan in
Google Scholar
PubMed
Search for other papers by Juliet C Gardiner in
Google Scholar
PubMed
Department of Genetics, Yeshiva University Albert Einstein College of Medicine, Bronx, New York, USA
Search for other papers by Elaine C Maggi in
Google Scholar
PubMed
Medicine, Albert Einstein College of Bronx, New York
Search for other papers by Shuyu Huang in
Google Scholar
PubMed
Search for other papers by Asha Adem in
Google Scholar
PubMed
Search for other papers by Svetlana Bagdasarov in
Google Scholar
PubMed
Search for other papers by Guiying Li in
Google Scholar
PubMed
Search for other papers by Sylvia Lee in
Google Scholar
PubMed
Search for other papers by Daniel Slegowski in
Google Scholar
PubMed
Search for other papers by Alyssa Exarchakis in
Google Scholar
PubMed
Search for other papers by James R Howe in
Google Scholar
PubMed
Search for other papers by Edmund C Lattime in
Google Scholar
PubMed
Medicine, Albert Einstein College of Bronx, New York
Search for other papers by Xingxing Zang in
Google Scholar
PubMed
Search for other papers by Steven K Libutti in
Google Scholar
PubMed
crucial roles in tumor development and clinical outcome. New clinical data show that tumor-infiltrating lymphocytes, particularly CD4 and CD8 T-cells, are prognostic and predictive in human GINETs and PNETs, suggesting that T-cells play a major anti
College of Medicine, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, College of Medicine, College of Medicine, Graduate Institute of Anatomy and Cell Biology, National Taiwan University, No. 1, Section 1, Jen‐Ai Road, Taipei, Taiwan
College of Medicine, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, College of Medicine, College of Medicine, Graduate Institute of Anatomy and Cell Biology, National Taiwan University, No. 1, Section 1, Jen‐Ai Road, Taipei, Taiwan
Search for other papers by Yu-Li Chen in
Google Scholar
PubMed
Search for other papers by Cheng-Yang Chou in
Google Scholar
PubMed
Search for other papers by Ming-Cheng Chang in
Google Scholar
PubMed
Search for other papers by Han-Wei Lin in
Google Scholar
PubMed
Search for other papers by Ching-Ting Huang in
Google Scholar
PubMed
Search for other papers by Shu-Feng Hsieh in
Google Scholar
PubMed
Search for other papers by Chi-An Chen in
Google Scholar
PubMed
College of Medicine, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, College of Medicine, College of Medicine, Graduate Institute of Anatomy and Cell Biology, National Taiwan University, No. 1, Section 1, Jen‐Ai Road, Taipei, Taiwan
College of Medicine, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, College of Medicine, College of Medicine, Graduate Institute of Anatomy and Cell Biology, National Taiwan University, No. 1, Section 1, Jen‐Ai Road, Taipei, Taiwan
Search for other papers by Wen-Fang Cheng in
Google Scholar
PubMed
underlying interaction between host immunity and tumor-associated cells is not clear ( Zhang et al . 2003 , Curiel et al . 2004 , Tomsová et al . 2008 ). The presence of tumor infiltrating lymphocytes has been positively correlated with survival in